Aurobindo Pharma gets USFDA nod for 2 drugs

G Naga Sridhar | | Updated on: Dec 06, 2021

Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Ibandronate Sodium Injection.

It is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Boniva Injection of Hoffmann-La Roche, Inc. Ibandronate Sodium Injection is indicated for the treatment of osteoporosis in postmenopausal women.

Aurobindo has also received final approval from the USFDA to manufacture and market Omeprazole Delayed-release Capsules.

It is bioequivalent and therapeutically equivalent to the reference listed drug product Prilosec Delayed-release Capsules of AstraZeneca Pharmaceuticals.

The tablets are indicated for short-term treatment of active duodenal ulcer in adults. The product has an estimated market size of $422 million for the 12 months ended June 30, 2015, according to IMS.

Published on August 20, 2015
COMMENTS
This article is closed for comments.
Please Email the Editor

You May Also Like

Recommended for you